Pharmacyclics Inc

Pharmacyclics — Technical Presentation (June 2013)

26 slides from Pharmacyclics's technical presentation, Jun 20, 2013

  1. Slide 1: A Prospective Multicenter Phase II Study of Ibrutinib in Relapsed and Refractory WM

    A PROSPECTIVE MULTICENTER PHASE Il STUDY OF THE BRUTON’S TYROSINE KINASE INHIBITOR IBRUTINIB IN PATIENTS WITH RELAPSED AND REFRACTORY WALDENSTROM’S MACROGLOBULINEMIA. LIAN XU, IB LAUBACH, ER CENTER CAL CENTER ANFORD

  2. Slide 2: A new era for Waldenstrom macroglobulinemia: MYD88 L265P

    A new era for Walenstron macroglobulinemia: MYDB8 L26SP BLOOD 2013

  3. Slide 3: MYD88 L265P Somatic Mutation

    MYD88 L265P SOMATIC MUTATION C to Gat position 38186241 Acquired UPD at 3p22 at 3p22.2 ‘. H 2 a 3 Q = Fd a & a 3 = a WGS and Sanger sequencing: 91% of WM pts have MYD88 L265P! Treon et al, NEJM 2012

  4. Slide 4: MYD88 L265P in WM/IgM MGUS

    MYD88 L265P IN WM/IgM MGUS WGS/ SANGER Xu AS-PCR Gachard PCR Varettoni AS-PCR Landgren Sanger Jiminez AS-PCR Poulain PCR Ansell Sanger Willenbacher Sanger BMCD19* 91% BMCD19* 93% BM 70% BM 100% BM BM 86% BMCD19+ 80% NA 70% BM 86% 10% 54% 47% 54%** 87% ** Many patients may have WM diagnosis

  5. Slide 5: Receptor/IL1R Signaling Pathway

    RECEPTOR/ IL1R SIGNALING ay SF PATHWAY “(im

  6. Slide 6: MYD88 Inhibitor Blocks p65 NFKB Nuclear Localization

    Control MYD88 INHIBITOR A “ «© BLOCKS P65 Py: NFKB NUCLEAR LOCALIZATION 5, ©. Cprwl 23 IN L265P EXPRESSING WM CELLS. A. BCWM.1 B. MWCL-1 MYD88 Inhibitor Treon et al, NEJM 2012

  7. Slide 7: Disruption of MYD88 Signaling Induces Apoptosis of L265P Expressing WM Cells

    DISRUPTION OF MYD88 SIGNALING INDUCES APOPTOSIS OF L265P EXPRESSING WM CELLS I re ; aobl jee —————

  8. Slide 8: MYD88 Binds to Bruton's Tyrosine Kinase (BTK)

    MYD88 BINDS TO BRUTON’S TYROSINE KINASE (BTK) IN L265P EXPRESSING WM CELLS p a a re toe PE SPOKE SH SF ors wave POS SF . 161 OS 328 80 129 170 191 264 | pyDes/BTK IB: BTK : — -- a sare rs = BOwM.A MWCL-1 OCHLy3OCHLy19.~—Ramos_-—-RPMI-8226 LELELELEEEPES IP: 196 MYO88 ee a oo... YANG ETAL, ASH 2012 A.

  9. Slide 9: MYD88 Induces BTK Activation in WM Cells

    MYD88 INDUCES BTK ACTIVATION IN WM CELLS A B — egg IGP sg ——— aa Fe LPS GE eS SBE [—— —___} =

  10. Slide 10: Schema for Multicenter Phase II Study of Ibrutinib in Relapsed Refractory WM

    SCHEMA FOR MULTICENTER PHASE II STUDY OF IBRUTINIB INRELAPSED REFRACTORY WM Informed Consent and Registration Ibrutinib 420 mg po daily Progressive Disease or Stable Disease or Unacceptable Toxicity Response Stop Ibrutinib Event Monitoring Event Monitoring

  11. Slide 11: Ibrutinib: Small Molecule Inhibitor of BTK

    IBRUTINIB: Small Molecule Inhibitor of BTK Inactivates BTK through covalent binding to cysteine-481 near the ATP binding domain of BTK. Orally bioavailable with daily dosing resulting in 24-hr target inhibition. Blocks IkBa and NFKB p65 signaling in WM cells. Induces apoptosis of MYD88 L265P express

  12. Slide 12: Eligibility: Key Inclusion Criteria

    ELIGIBILITY: KEY INCLUSION CRITERIA = WM with symptomatic disease using consensus criteria = Atleast one prior therapy for WM = Adequate organ and marrow function: — Absolute neutrophil count > 1,000/mm* — Platelets > 50,000/mm? — Hemoglobin > 8 g/dL — Total bilirubin < 1.5 mg/dL or < 2 mg/dL if due

  13. Slide 13: Eligibility: Key Exclusion Criteria

    ELIGIBILITY: KEY EXCLUSION CRITERIA Anticoagulation with Warfarin Treatment with strong CYP3A4/5 and/or CYP 2D6 inhibitors Any medical condition or organ system dysfunction which could interfere with absorption or metabolism of ibrutinib Grade > 2 toxicity from prior anti-cancer therapy Known CNS ly

  14. Slide 14: Patient Characteristics at Baseline (n=35)

    PATIENT CHARACTERISTICS AT BASELINE (n=35) Range Age (yrs) 44-86 Prior therapies 1-6 Refractory 12 (34%) NA Hematocrit (%) 30.8 26.7-39.2 Serum IgM (mg/dL) 3190 735-8390 M-protein (g/dL) 2.08 0.5-5.4 B2M (mg/dL) 44 1.3-14.2 BM Involvement (%) 70 5-95 Adenopathy or Splenomegaly 29 (83%) NA Treon et a

  15. Slide 15: Primary Reason for Treatment Initiation (n=35)

    PRIMARY REASON FOR TREATMENT INITIATION (n=35) Anemia 26 (74%) Bicytopenia 4 (11%) Hyperviscosity 1 (3%) Nephropathy 1 (3%) IgM Neuropathy 1 (3%) Adenopathy 1 (3%) Other 1 (3%) Treon et al, ICML-12, Lugano 2013

  16. Slide 16: Serial Changes in Serum IgM (n=35)

    SERIAL CHANGES IN SERUM IgM (N=35) a = > c= = > E 2 5 no lM Baseline lM Cycle 2 IgM Cycle 3 IgM Cycle 6 IgM Cycle 9 leM Cycle 12 Data Lock June 3, 2013 Treon et al, ICML-12, Lugano 2013

  17. Slide 17: Changes in Serum IgM Following Ibrutinib in Relapsed/Refractory WM Patients

    CHANGES IN SERUM IgM FOLLOWING IBRUTINIB IN 35 RELAPSED/REFRACTORY WM PATIENTS 3,190 to 1,232 mg/dL; p=5.1 x 10-9 | 26 Cycles Best Response ‘3000 IgM Baseline IgM Best Response 000 7000 6000 = mate 12.3 6 5 67 8 9 1011 1219 46 15 16 17 18 19 20 24 22 29 24 25 26 27 28 29 3031-92 39:34 95, Data Lock

  18. Slide 18: Serial Changes in Hematocrit (n=35)

    SERIAL CHANGES IN HEMATOCRIT (n=35) BS 5 2 © = ® x Baseline Cycle 2 Cycle 3 Cycle 6 cycle9 Cycle 12 Data Lock June 3, 2013 Treon et al, ICML-12, Lugano 2013

  19. Slide 19: Changes in Hematocrit Following Ibrutinib

    CHANGES IN HEMATOCRIT FOLLOWING IBRUTINIB IN 35 RELAPSED/REFRACTORY WM PATIENTS 30.8% to 39.7%; p=1.1 x 10-1 Best Responds Hct Baseline Hct Best Response

  20. Slide 20: Serial Change in % BM Disease Burden

    SERIAL CHANGE IN % BM DISEASE BURDEN AT CYCLE 6 OF IBRUTINIB TREATMENT 70% to 40%; p=0.0004 BM (IT%) Baseline BM Cycle 6 Data Lock June 3, 2013 Treon et al, ICML-12, Lugano 2013 20

  21. Slide 21: Best Clinical Responses to Ibrutinib

    BEST CLINICAL RESPONSES TO IBRUTINIB (>6 CYCLES; N=35) Data Lock June 3, 2013 (%) 11.4 PR 54.3 MR 17.1 sD 14.3 NON- 29 RESPONDER ORR: 83% MAJOR RR (> PR): 66% Treon et al, ICML-12, Lugano 2013

  22. Slide 22: At >6 Cycles: Participants Discontinued Protocol Therapy

    AT >6 CYCLES: 3 participants discontinued protocol therapy: *1 Non-responder (MYD88 WT). *1 MDS/RAEB (Heavily pretreated; Pre-existing 5 q- in 10% metaphases; PR, progressed off therapy). *1 Recurring thrombocytopenia- aggravated by splenic entrapment, resolved after splenectomy; Stable Disease off

  23. Slide 23: Possibly, Probably, or Likely Related Adverse Events (n=35)

    POSSIBLY, PROBABLY, OR LIKELY RELATED (N=35) ADVERSE EVENT >GRADE 2 GRADE3 GRADE 4 THROMBOCYTOPENIA 6(17.1%) 3(8.6%) 0 (0.0%) NEUTROPENIA 6 (17.1%) 2(5.7%) 1 (2.8%) HEMATOMA 1 (2.9%) 0(0.0%) 0 (0.0%) EPISTAXIS* 1(2.9%) 0(0.0%) 0(0.0%) STOMATITIS 1 (2.9%) 1 (2.9%) 1 (2.9%) ATRIAL FIBRILLATION 1 (2.9%

  24. Slide 24: FDA Grants 'Breakthrough' Designation for Ibrutinib

    FDA GRANTS ‘BREAKTHROUGH’ DESIGNATION FOR IBRUTINIB FDA granted breakthrough therapy designation to ibrutinib for patients with mantle cell lymphoma and Waldenstrém’s macroglobulinemia. See Also The designation, created in 2012, allows for expedited development and review of drugs shown in preclinic

  25. Slide 25: Take Home...

    Take Home... MYD88 L265P is present >90% of WM patients and triggers activation of Bruton’s Tyrosine Kinase (BTK) in WM cells. The BTK inhibitor ibrutinib is associated with rapid reduction of serum IgM and improvements in HCT, and an ORR of 83% in relapsed/refractory patients. Level of improvement

  26. Slide 26: Acknowledgements

    ACKNOWLEDGEMENTS ‘Thanks to Peter S. Bing, MiD., the International Waldenstrom’s Macroglobulinemia Foundation, Coyote Fund for WM, Waldenstrom’s Cancer Fund and NIH Spore Funding, Bailey Family Fund for WM, D’ Amato Family Fund for Genomic Discovery, Edward and Linda Nelson Fund for WM Research, Bau

Pharmacyclics — Technical Presentation (June 2013) on 6ix